Abbott today announced an update to its latest FreeStyle Libre 2 app, which will allow Canadians who use the FreeStyle Libre 2* system to get real-time minute-by-minute glucose readings automatically† displayed on the app.

Abbott has been recognized as one of "Montréal's Top Employers" for 2023 in Mediacorp Canada's annual employer survey.

Abbott today announced that its FreeStyle Libre 2 flash glucose monitoring system* is now reimbursed under the Régie de l’assurance maladie du Quebec (RAMQ) for Quebec residents aged four and over who manage their diabetes (type 1 or type 2) with multiple daily injections of insulin~.

Abbott (NYSE: ABT) announces the Health Canada licencing† of NeuroSphere™ Virtual Clinic, a remote programming technology that is the first of its kind in Canada and is compatible with Abbott’s suite of neuromodulation technologies.

Abbott (NYSE: ABT) today announced it has introduced in Canada the EnSite™ X EP System with EnSite Omnipolar Technology (OT), a new cardiac mapping platform designed to help physicians better treat abnormal heart rhythms, also known as cardiac arrhythmias. This new platform allows for the creation of a 3D model of the patient's cardiac anatomy in real-time, improving how physicians identify and then treat areas of the heart where abnormal rhythms originate.